Newsticker

Oktober 24, 2023 Corporate

ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics

Oktober 18, 2023 Partnerships

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

Juli 31, 2023 Partnerships

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

Juni 15, 2023 Corporate

ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023

Juni 13, 2023 Production

ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer

Juni 05, 2023 Corporate

ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

April 27, 2023 Partnerships

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

April 17, 2023 Corporate

ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey

View all news »

Our Company

Pipeline

In Targeted Cancer Diagnostics & Therapy

Career

Be Part Of Our
Company

Targeted
Radionuclide
Therapy

In Precision Oncology

Products

Radiopharmaceutical & Radioisotope Business

Diversity

Diversity at ITM

Diese Webseite nutzt Cookies

PASSION FOR PRECISION.

Newsticker

ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023

ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer

ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey

Inside Stories

Our Company

Pipeline

Career

Targeted
Radionuclide
Therapy

Products

Diversity

Diese Webseite nutzt Cookies

Newsticker

ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023

ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer

ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey

Inside Stories

Our Company

Pipeline

Career

Targeted Radionuclide Therapy

Products

Diversity

Targeted
Radionuclide
Therapy